Rapid cardioversion for acute atrial fibrillation
Authors:
Abstract
Questions about the safety of vernakalant remainKeywords
This publication has 9 references indexed in Scilit:
- Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trialBMJ, 2025
- Effectiveness and safety of vernakalant vs flecainide for cardioversion of atrial fibrillation in the emergency department: the VERITA studyInternational Journal of Emergency Medicine, 2025
- Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: assessing net clinical benefitEuropean Heart Journal Supplements, 2024
- Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM StudyCardiovascular Drugs and Therapy, 2020
- Epidemiology of Atrial Fibrillation in the 21st CenturyCirculation Research, 2020
- Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trialBMC Cardiovascular Disorders, 2016
- The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the U.S.A?Current Cardiology Reviews, 2014
- A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial FibrillationJACC, 2011
- Vernakalant Hydrochloride for Rapid Conversion of Atrial FibrillationCirculation, 2008